AI Article Synopsis
- * Standard treatments like palliative chemotherapy and immunotherapy have shown limited effectiveness for this type of cancer.
- * A case study is presented where a patient with pancreatic cancer improved after receiving a combination of anti-PD-1 immunotherapy and chemotherapy.
Article Abstract
Pancreatic cancer is digestive cancer with limited therapeutic options and a poor outcome. Pancreatic cancer has a high mortality rate, with a 5-year survival rate of less than 5%. The median survival after metastasis of the disease is less than 6 months. Studies have revealed that the standard treatment, including palliative chemotherapy or immunotherapy, is not significantly effective for pancreatic cancer. Herein, we report a case of pancreatic cancer who benefited from a combination of anti-PD-1 immunotherapy and chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670360 | PMC |
| http://dx.doi.org/10.1097/CAD.0000000000001232 | DOI Listing |
Publication Analysis
Top Keywords
pancreatic cancer
20
cancer
6
pancreatic
5
tumor-mutation burden
4
burden marker
4
marker immunotherapy
4
immunotherapy pancreatic
4
cancer case
4
case report
4
report literature
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!